Literature DB >> 22568247

[Clinical efficacy of bushen huoxue qubi decoction on treatment of knee-osteoarthritis and its effect on hemarheology, anti-inflammation and antioxidation].

Ge Gao1, Hong Wu, Jing Tian, Jinfeng Du, Xi Xie, Jiesheng Gao.   

Abstract

OBJECTIVE: To prove the clinical effect and mechanism of Bushen Huoxue Qubi Decoction on treatment of knee-osteoarthritis.
METHOD: Ninty-six knee-osteoarthritic patients accompanied with symptoms of liver and kidney deficiency and blocked main and collateral channels were divided into two groups randomly. Patients in the treatment group (n = 48) were administrated by Bushen Huoxue Qubi Decoction one bag/day for four weeks; and those in the control group (n = 48) were given diacerein (50 mg Bid, Po) and celecoxib (0.2 Qd, Po) for four weeks. The changes of VAS score, Womac score, relative viscosity, aggregation index and IL-1beta, NO, iNOS, LPO, SOD in serum were observed. Adverse effects were determined during follow-up visit and detection for blood routine and hepatic and renal functions. RESULT: Its clinical control rates as per Western medicine and TCM standards for treatment of knee-osteoarthritis and effective rate were 33.3%, 37.5% and 97.9% respectively, which was remarkably higher than those in the control group (18.8%, 20.8% and 95.5%). Their difference showed statistical significance, P<0.05 or 0.01. Bushen Huoxue Qubi Decoction had an effect in obviously improving hemarheological index in 42 days and inhibiting IL-1beta, NO, iNOS and LPO better than the control group, by the contrast of 58.6% vs 47.3%, 50.1% vs 36%, 55.1% vs 41.9% and 46.7% vs 20.6% (P<0.05 or P<0.01). The treatment group also displayed a higher SOD capability the control group (2 514.71 +/- 812.65) vs (2 013.41 +/- 781.3), (P<0.01). Both groups reported no adverse effect.
CONCLUSION: Bushen Huoxue Qubi Decoction has a better efficacy on knee-OA than traditional treatment methods (diacereinand + celecoxib) and showed no adverse effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22568247

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  7 in total

1.  Role of clinical nursing path combined with traditional Chinese dialectical nursing in the treatment of knee osteoarthritis.

Authors:  Chunyan Zhang; Chunxia Sun
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 2.  Oral herbal therapies for treating osteoarthritis.

Authors:  Melainie Cameron; Sigrun Chrubasik
Journal:  Cochrane Database Syst Rev       Date:  2014-05-22

3.  Comparative efficacy and safety of Chinese herbal medicine for knee osteoarthritis: A protocol for systematic review and network meta-analysis.

Authors:  Lei Yang; Bo-Yu Wu; Lu Ma; Zheng-Dong Li; Hui Xiong
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

Review 4.  Traditional Chinese Medications for Knee Osteoarthritis Pain: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Bo Chen; Hongsheng Zhan; Jolanta Marszalek; Mei Chung; Xun Lin; Min Zhang; Jian Pang; Chenchen Wang
Journal:  Am J Chin Med       Date:  2016-05-24       Impact factor: 4.667

Review 5.  Evidence of Chinese herbal medicine Duhuo Jisheng decoction for knee osteoarthritis: a systematic review of randomised clinical trials.

Authors:  Wenming Zhang; Shangquan Wang; Ranxing Zhang; Yuanyuan Zhang; Xinjian Li; Yanping Lin; Xu Wei
Journal:  BMJ Open       Date:  2016-01-04       Impact factor: 2.692

6.  Pharmacokinetics and tissue distribution study of tanshinone IIA after oral administration of Bushen Huoxue Qubi granules to rats with blood stasis syndrome.

Authors:  Yuanqing Wang; Jianye Yan; Shunxiang Li; Xiong Cai; Wei Wang; Kun Luo; Dan Huang; Jiesheng Gao
Journal:  Pharmacogn Mag       Date:  2014-07       Impact factor: 1.085

7.  Effects of bushen huoxue method for knee osteoarthritis: A protocol for systematic review and meta-analysis.

Authors:  Guocai Chen; Xiangling Ye; Yingxin Guan; Wengang Liu; Jianping Du; Nan Yao; Xuemeng Xu
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.